MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its fourth quarter 2022 financial results on March 15, 2023, after market close. A conference call to discuss these results and corporate progress will follow at 4:30 pm ET on the same day. Investors can register in advance for telephone participation, receiving a confirmation email with access details. A listen-only webcast will also be available on the company's website under the Investor Relations section. MacroGenics is focused on developing innovative monoclonal antibody therapeutics for cancer treatment, leveraging proprietary antibody technology and strategic collaborations.
- None.
- None.
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2022 after the market closes on Wednesday, March 15, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Wednesday, March 15, 2023, at 4:30 pm ET.
Conference Call Information
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events-and-presentations/events. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
###
FAQ
When will MacroGenics report its fourth quarter 2022 financial results?
What time is the conference call for MacroGenics' financial results?
How can I participate in the MacroGenics conference call?
Where can I find the webcast of the MacroGenics conference call?
